Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group.

@article{Glaspy1997ImpactOT,
  title={Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group.},
  author={John A. Glaspy and Ronald A. Bukowski and David Steinberg and Charles Taylor and Simon Tchekmedyian and Saroj Vadhan-Raj},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1997},
  volume={15 3},
  pages={
          1218-34
        }
}
PURPOSE To study the impact of Procrit (epoetin alfa; Amgen Inc, Thousand Oaks, CA) on quality of life, transfusion requirements, and hemoglobin in anemic cancer patients receiving chemotherapy. PATIENTS AND METHODS More than 500 community-based oncologists enrolled 2,342 patients with malignancies undergoing cytotoxic chemotherapy in an open-label study. Patients were treated with epoetin alfa 150 U/kg three times weekly, which could be doubled if the therapuetic response was judged… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 193 CITATIONS

Similar Papers

Loading similar papers…